Printer Friendly

RHEUMATOID ARTHRITIS CLINICAL TRIAL APPROVED BY FDA

 RHEUMATOID ARTHRITIS CLINICAL TRIAL APPROVED BY FDA
 SEATTLE, Jan. 8 /PRNewswire/ -- IMRE Corp. (NASDAQ: IMRE) today


announced that the U.S. Food and Drug Administration has approved a clinical trial of its PROSORBA(R) column for the treatment of patients with rheumatoid arthritis. The clinical trial will help determine whether PROSORBA(R) column treatments would be therapeutic for patients with rheumatoid arthritis, a disease which affects approximately 2,500,000 people in the United States. This trial will begin immediately.
 The company intends to conduct a number of clinical trials during 1992. These include the treatment of patients with lupus, multiple sclerosis, myasthenia gravis, kidney transplants and certain cancers. All of these trials have been approved by the FDA.
 IMRE Corp. is a Seattle-based medical products company that is a pioneer and the leader in the field of therapeutic extracorporeal immunoadsorption, a process of treating a diseased patient's blood outside the body.
 -0- 1/8/92
 /CONTACT: Lois Yoshida of IMRE Corp., 206-298-9400/
 (IMRE) CO: IMRE Corp. ST: Washington IN: MTC SU:


JH-TB -- SE011 -- 7622 01/08/92 09:10 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 8, 1992
Words:181
Previous Article:NORTH AMERICAN BIOLOGICALS AWARDED $9 MILLION IN FEDERAL CONTRACTS FOR AIDS SCREENING AND OTHER BLOOD TESTING AND PRODUCTS
Next Article:GENERAL KINETICS NEGOTIATES AMENDMENT TO REVOLVING CREDIT FACILITIES WITH PRINCIPAL BANK
Topics:


Related Articles
THE IMMUNE RESPONSE CORPORATION BEGINS CLINICAL TRIAL OF NEW RHEUMATOID ARTHRITIS TREATMENT
RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN REPORTED BY IMRE CORPORATION
RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN SHOW LONG-TERM EFFECTS
THE IMMUNE RESPONSE CORPORATION BEGINS RHEUMATOID ARTHRITIS PHASE II CLINICAL TRIAL
IMRE CORPORATION ANNOUNCES POSITIVE RHEUMATOID ARTHRITIS CLINICAL TRIAL RESULTS
IMRE CORPORATION RECEIVES CONDITIONAL APPROVAL TO BEGIN PIVOTAL RHEUMATOID ARTHRITIS CLINICAL TRIAL
COMPANY BEGINS CLINICAL STUDIES IN RUSSIA FOR NEW TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER AUTOIMMUNE DISEASES
Aventis and Vertex discontinue arthritis drug trial.
Aventis and Vertex discontinue arthritis drug trial.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters